Join to View Full Profile
55 Fruit StBoston, MA 02114
Phone+1 617-724-4000
Dr. Piotrowska is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Yale School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2027
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Start of enrollment: 2016 Jun 01
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Start of enrollment: 2017 Oct 31
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
Publications & Presentations
PubMed
- ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon, Yong-Kek Pang, Soon Hin How
Cancer Discovery. 2026-06-01 - Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, Adrianus J de Langen, Xiuning Le
European Journal of Cancer. 2026-05-18 - BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.Yves A Millet, Alexander I Spira, Christina S Baik, Min Hee Hong, Elaine Shum
Molecular Cancer Therapeutics. 2026-05-13
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
- EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasLecia V Sequist, Zofia Piotrowska, Clinical Cancer Research
Press Mentions
A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-Mutated NSCLC and Acquired MET Amplification After Progression on a First-Line EGFR TKIJanuary 16th, 2026- Withdrawn NSCLC Drug: Was Ambitious Phase 3 Trial Design to Blame?March 5th, 2025
- Medical Mysteries: She Went Undiagnosed Until Almost Too LateMay 25th, 2024
Grant Support
- Non-genomic resistance mechanisms in EGFR-mutant lung cancerMASSACHUSETTS GENERAL HOSPITAL2009–2027
Other Languages
- French, Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
